Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

The donation will from Pfizer will allow Moores Cancer Center to launch the Early Detection and Prevention of Cancer Initiative to increase awareness of and access to cancer prevention and screening ...

Pfizer announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company ...

Pfizer and Arvinas’ estrogen receptor (ER ... Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast cancer who had already tried CDK 4/6 inhibitors and endocrine therapy.

Also Read: Pfizer Shares Are Down Today ... Hodgkin lymphoma is a type of cancer that affects cells in the lymphatic system. Advanced (stage 3 and 4) CD30-positive Hodgkin lymphoma most commonly ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Vepdegestrant met the primary endpoint in ESR1-mutant breast cancer, significantly improving progression-free survival over fulvestrant. The trial did not achieve statistical significance for PFS ...